1. Home
  2. CHEK vs PRPO Comparison

CHEK vs PRPO Comparison

Compare CHEK & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHEK
  • PRPO
  • Stock Information
  • Founded
  • CHEK 2004
  • PRPO N/A
  • Country
  • CHEK Israel
  • PRPO United States
  • Employees
  • CHEK N/A
  • PRPO N/A
  • Industry
  • CHEK Medical Electronics
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • CHEK Health Care
  • PRPO Industrials
  • Exchange
  • CHEK Nasdaq
  • PRPO Nasdaq
  • Market Cap
  • CHEK 4.4M
  • PRPO N/A
  • IPO Year
  • CHEK 2015
  • PRPO N/A
  • Fundamental
  • Price
  • CHEK N/A
  • PRPO $11.79
  • Analyst Decision
  • CHEK
  • PRPO
  • Analyst Count
  • CHEK 0
  • PRPO 0
  • Target Price
  • CHEK N/A
  • PRPO N/A
  • AVG Volume (30 Days)
  • CHEK 28.3K
  • PRPO 9.8K
  • Earning Date
  • CHEK 08-14-2025
  • PRPO 08-12-2025
  • Dividend Yield
  • CHEK N/A
  • PRPO N/A
  • EPS Growth
  • CHEK N/A
  • PRPO N/A
  • EPS
  • CHEK N/A
  • PRPO N/A
  • Revenue
  • CHEK N/A
  • PRPO $20,029,000.00
  • Revenue This Year
  • CHEK N/A
  • PRPO N/A
  • Revenue Next Year
  • CHEK N/A
  • PRPO N/A
  • P/E Ratio
  • CHEK N/A
  • PRPO N/A
  • Revenue Growth
  • CHEK N/A
  • PRPO 26.67
  • 52 Week Low
  • CHEK $0.56
  • PRPO $3.90
  • 52 Week High
  • CHEK $3.04
  • PRPO $12.45
  • Technical
  • Relative Strength Index (RSI)
  • CHEK 41.81
  • PRPO 65.45
  • Support Level
  • CHEK $0.75
  • PRPO $10.60
  • Resistance Level
  • CHEK $0.86
  • PRPO $11.70
  • Average True Range (ATR)
  • CHEK 0.03
  • PRPO 0.60
  • MACD
  • CHEK 0.00
  • PRPO -0.08
  • Stochastic Oscillator
  • CHEK 19.59
  • PRPO 79.57

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: